Muscarinic receptor 1 allosteric modulators stimulate colorectal emptying in dog, mouse and rat and resolve constipation

Neurogastroenterol Motil. 2019 Nov;31(11):e13692. doi: 10.1111/nmo.13692. Epub 2019 Aug 2.

Abstract

Background: Because M1 muscarinic receptors are expressed by enteric neurons, we investigated whether positive allosteric modulators of these receptors (M1PAMs) would enhance colorectal propulsion and defecation in dogs, mice, and rats.

Methods: The potencies of the M1PAMs, T662 or T523, were investigated using M1 receptor-expressing CHO cells. Effectiveness of M1PAMs on defecation was investigated by oral administration in mice and rats, by recording propulsive contractions in anaesthetized rats and by recording high amplitude propagating contractions in dogs.

Key results: PAM EC50 values in M1 receptor-expressing CHO cells were 0.7-1.8 nmol/L for T662 and 8-10 nmol/L for T523. The compounds had 1000-fold lower potencies as agonists. In anesthetized rats, both compounds elicited propulsive colorectal contractions, and in dogs, mice, and rats, oral administration increased fecal output. No adverse effects were observed in conscious animals. M1PAMs triggered propagated high amplitude contractions and caused defecation in dogs. Nerve-mediated contractions were enhanced in the isolated mouse colon. M1PAMs were equi-effective in rats with or without the pelvic nerves being severed. In two models of constipation in mice, opiate-induced constipation and constipation of aging, defecation was induced and constipation was reversed.

Conclusion and inferences: M1PAMs act at targets sites in the colorectum to enhance colorectal propulsion. They are effective across species, and they reverse experimentally induced constipation. Previous studies have shown that they are safe in human. Because they provide an enhancement of physiological control rather than being direct agonists, they are predicted to provide effective treatment for constipation.

Keywords: colokinetics; constipation; defecation; enteric nervous system; muscarinic receptors.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Oral
  • Animals
  • CHO Cells
  • Colon / drug effects
  • Constipation / drug therapy*
  • Cricetulus
  • Dogs
  • Gastrointestinal Agents / administration & dosage
  • Gastrointestinal Agents / pharmacology*
  • Gastrointestinal Agents / therapeutic use
  • Gastrointestinal Motility / drug effects*
  • Gastrointestinal Motility / physiology
  • Mice
  • Pyrazoles / administration & dosage
  • Pyrazoles / pharmacology*
  • Pyrazoles / therapeutic use
  • Pyridines / administration & dosage
  • Pyridines / pharmacology*
  • Pyridines / therapeutic use
  • Quinazolines / administration & dosage
  • Quinazolines / pharmacology*
  • Quinazolines / therapeutic use
  • Rats
  • Receptor, Muscarinic M1 / agonists*
  • Rectum / drug effects

Substances

  • Gastrointestinal Agents
  • Pyrazoles
  • Pyridines
  • Quinazolines
  • Receptor, Muscarinic M1
  • muscarinic receptor 1 allosteric modulator T662